1) Cummings JL, Schneider L, Tariot PN, et al:Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry 161:532-538, 2004
2) Freedman M:Frontotemporal dementia:Recommendations for therapeutic studies, designs, and approaches. Can J Neurol Sci 34(Suppl 1):S118-124, 2007
3) Holmes C, Wilkinson D, Dean C, et al:The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 63:214-219, 2004
4) Kertesz A, Morlog D, Light M, et al:Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord 25:178-185, 2008
5) Lampl Y, Sadeh M, Lorberboym M:Efficacy of acetylcholinesterase inhibitors in frontotemporal dementia. Ann Pharmacother 38:1967-1968, 2004
6) Mendez MF, Shapira JS, McMurtray A, et al:Preliminary findings:Behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry 15:84-87, 2007
7) Moretti R, Torre P, Antonello RM, et al:Rivastigmine in frontotemporal dementia:An open-label study. Drugs Aging 21:931-937, 2004
8) Neary D, Snowden JS, Gustafson L, et al:Frontotemporal lobar degeneration:A consensus on clinical diagnostic criteria. Neurology 51:1546-1554, 1998
9) Shinagawa S, Ikeda M, Fukuhara R, et al:Initial symptoms in frontotemporal dementia and semantic dementia compared with Alzheimer's disease. Dement Geriatr Cogn Disord 21:74-80, 2006
10) Vossel KA, Miller BL:New approaches to the treatment of frontotemporal lobar degeneration. Curr Opin Neurol 21:708-716, 2008